Botanix Pharma(ASX:BOT) Managements

  • Symbol:ASX:BOT
  • Sector:Healthcare
  • Industry:Biotechnology
  • CEO:Vince Ippolito
  • Founded:2002
Categories:

Botanix Pharma(ASX:BOT) Managements

Matthew Callahan

Founder and Executive Director

Matt Callahan is an experienced life sciences executive, as well as being the founding CEO of iCeutica Inc and Churchill Pharma Inc. He has more than 20 years legal, IP and investment management experience, and is a director of Glycan Bioscience LLC.

Callahan has also worked as an investment director for two venture capital firms focused on investing in life sciences, clean technology and other sectors.
Vince Ippolito

President & Executive Chairman

Vince Ippolito is a leading pharmaceutical expert who has over 30 years of experience in the industry, including more than 20 years in dermatology.

Throughout his career, he has launched more than 20 brands in dermatology and aesthetic medicine, along with playing a leading role in two of the largest dermatology acquisitions—with a combined valuation of $7.8 billion—completed in the past decade.
Dr Bill Bosch

Executive Director & Chief Scientific Officer

Dr Bill Bosch is a seasoned pharmaceutical executive with more than 20 years of experience in the industry, with a specific focus on the applications of nano technology to drug product development.

He is a co-inventor of the NanoCrystal® and SoluMatrix™ technologies, along with being instrumental to the development of the 3 FDA approved products that make use of his delivery system.
Ric Peterson

Chief Financial Officer

Ric Peterson has extensive experience with the dermatology field, capital markets and corporate governance. Previously, he held the position of CFO at Dermavant Sciences, and also served as a CFO at dermatology companies like Sienna Biopharmaceuticals, Novan and Medicis Pharmaceutical.

In these roles, Peterson oversaw duties relating to finance, business development, business operations and information technology.
Dr Michael Thurn

Executive Director

Michael Thurn is an experienced senior executive with 15 years of managerial and Board experience. He has a Doctor of Philosophy from University of Technology Sydney and was a Postdoctoral Research fellow at the Australian Institute of Marine Science.

Thurn has a background in drug regulation and the biopharmaceutical industry, which has included senior roles with both listed and private companies. He has worked extensively with life science start-ups across a range of technology platforms, as well as having experience in drug discovery, preclinical and clinical development.

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Become a Patron below and support us in covering the latest marijuana news!